EyePoint (EYPT) Change in Receivables (2011 - 2026)
EyePoint (EYPT) posted Change in Receivables of $5.0 million for Q1 2026, down 54.05% sequentially from $10.8 million in Q4 2025, and up 244.52% YoY from $1.4 million in Q1 2025.
Analysis
EyePoint (EYPT) Change in Receivables (2011 - 2026) Analysis & Trends
EyePoint has reported Change in Receivables for 16 years, with the latest figure at $5.0 million in Q1 2026.
- Quarterly Change in Receivables rose 244.52% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (up 355.9% YoY) and the FY2025 annual result came in at $10.7 million, up 4271.72% from the prior year.
- Change in Receivables fell to $5.0 million in Q1 2026 per EYPT's latest filing, from $10.8 million in the prior quarter.
- Over five years, Change in Receivables peaked at $10.8 million in Q4 2025 and troughed at -$10.7 million in Q3 2023.
- A 5-year average of $240882.4 and a median of $269000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables slumped 2820.65% in 2023, then jumped 678.69% in 2025.
- Over 5 years, Change in Receivables stood at -$6.3 million in 2022, then soared by 104.28% to $269000.0 in 2023, then slumped by 792.57% to -$1.9 million in 2024, then surged by 678.69% to $10.8 million in 2025, then tumbled by 54.05% to $5.0 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $5.0 million, $10.8 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -19.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.25 Mn |
| Mar 31, 2026 | 4.95 Mn |
| Dec 31, 2025 | 10.78 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 180,000.00 |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | -1.86 Mn |
| Sep 30, 2024 | 939,000.00 |
| Jun 30, 2024 | -3.09 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | -10.75 Mn |
| Jun 30, 2023 | 979,000.00 |
| Mar 31, 2023 | -4.93 Mn |
| Dec 31, 2022 | -6.28 Mn |
| Sep 30, 2022 | -368,000.00 |
| Jun 30, 2022 | 6.37 Mn |
| Mar 31, 2022 | 2.94 Mn |
| Dec 31, 2021 | 5.98 Mn |
| Sep 30, 2021 | -1.32 Mn |